How to Prepare Performance Verification Documentation for Overseas Registration of POCT Products?

Overview

This FAQ addresses the preparation of performance verification documentation for overseas registration of POCT products. It covers the core requirements, regulatory pathways, common pitfalls, and a practical preparation checklist for medical device manufacturers, distributors, CROs, and regulatory affairs teams.

Applicable Scenarios and Core Questions

Companies searching for information on preparing performance verification documents for POCT overseas registration typically need to determine whether existing documentation can support submissions to target markets, whether a local agent or authorized representative is required, why timelines are being extended, and what issues may affect product launch. This question often involves product classification, registration pathway, evidence chain, labeling localization, and post-market maintenance responsibilities.

If a company plans to enter multiple GHWP member countries or markets in Southeast Asia, the Middle East, or Latin America, answering only one country’s process is insufficient. A more valuable approach is to first build a reusable core technical file—including quality system evidence, performance verification, clinical evidence, and labeling—and then adapt it to each country’s regulatory requirements.

Registration Decision Logic

Step 1: Determine Regulatory Scope

Assess whether the product falls within the target country’s medical device regulatory scope. For example, Thailand TFDA classifies POCT as a medical device or in vitro diagnostic reagent, so the classification must be confirmed.

Step 2: Determine Risk Class

Classify the product’s risk level. Under EU IVDR, products are classified from Class A to D; most POCT products are Class B or C. The U.S. FDA categorizes into Class I, II, or III; most POCT products are Class II and require 510(k) clearance. Southeast Asian countries often adopt systems similar to WHO prequalification or their own national classification.

Step 3: Assess Reusability of Existing Data

For products with existing NMPA registration, CE certification (IVDD or IVDR), or FDA 510(k), certain performance reports may be partially applicable. However, verify alignment with the target country’s specific standards such as reference intervals, interference substances, and stability conditions.

Step 4: Define Registration Pathway and Applicant Responsibility

When using a local agent for registration, clarify the agent’s responsibilities and ensure that performance verification documentation is issued by the manufacturer or an authorized laboratory with full traceability.

Step 5: Design the Performance Verification Program

Based on ISO 18113, CLSI EP series, ICH Q2, and other applicable guidelines, design studies covering precision, accuracy, sensitivity, specificity, linearity, interference, cross-reactivity, stability (long-term, accelerated, open-vial, and transport), reference intervals, and clinical performance (where applicable).

Required Documentation and Evidence

The performance verification documentation should include at least the following:

• Analytical Performance Study Reports: Precision, accuracy, linearity, sensitivity, specificity, interference, cross-reactivity, etc. Include experimental methods, sample information, statistical analyses, and results.
• Clinical Performance Evaluation Report: For new biomarkers or products claiming diagnostic use, provide prospective or retrospective clinical study data compared with reference methods.
• Stability Study Report: Long-term, accelerated, open-vial, and transport simulation (ISTA or ASTM standards).
• Reference Interval Verification Report: Provide local population data or literature support for different populations (e.g., Asian, Middle Eastern, European, and North American).
• Quality Control Materials: Control material settings, testing frequency, and acceptance limits.
• Additional Data: Sample stability, inter-instrument comparison (e.g., different reagent lots or instruments).

All reports must include clear conclusions supporting the intended performance and claims. Documentation should be in the target country’s official language or English, with notarized translation if required.

Common Mistakes

• Not designing studies according to target-country standards (e.g., CLSI EP05, EP06, EP07 for FDA; ISO 18113 for EU IVDR may be accepted, but nuances differ).
• Missing local population reference interval data; directly referencing non-target population data can lead to deficiency letters.
• Inadequate stability conditions that do not match target environment (e.g., tropical countries require stricter temperature/humidity accelerated stability).
• Omitting transport simulation. POCT products often require cold-chain transport; failure to provide a transport simulation report may result in rejection.
• Insufficient clinical performance study sample size or low positive sample ratio, especially for low-incidence biomarkers; statistical rationale must be provided.
• Neglecting quality control materials and QC frequency; reviewers require a clear QC strategy.
• Reports issued by unauthorized laboratories without ISO 15189 or ISO 17025 accreditation may not be accepted.

Manufacturer Preparation Checklist

• Determine the target country’s registration requirements and performance standards (e.g., FDA CLSI, CE IVDR, TFDA, BPOM).
• Establish a project team involving regulatory, R&D, quality, and clinical personnel.
• Write the performance verification protocol, defining sample types, sample size, statistical methods, and acceptance criteria.
• Prepare samples, including positive, negative, interference, linearity, and QC materials, ensuring the matrix matches the clinical setting.
• Execute experiments, archive raw data, records, and original traces.
• Write final reports according to regulatory format, including summary, methods, results, discussion, and conclusions.
• For clinical performance evaluation, obtain ethics approval and informed consent.
• Use qualified third-party laboratories or accredited internal laboratories.
• Complete stability studies (long-term, accelerated, open-vial, transport).
• Compile all documentation into a technical file and submit to the local agent or authorized representative for review.
• Monitor regulatory updates regularly to ensure evidence remains valid.

AIMEILI Perspective

The most common misconception among manufacturers is that existing NMPA or CE reports can be directly converted. In reality, acceptance and specific standards for performance evidence vary significantly across countries. For example, the U.S. FDA requires CLSI methods for sensitivity and specificity calculations, while some Southeast Asian countries may only need a simple listing. However, if a reviewer finds insufficient data, additional testing will be requested. We recommend conducting a regulatory gap analysis early in the project to identify differences between the target country’s requirements and existing evidence, and to determine which studies need to be repeated.

Reusable data may include core analytical performance data (if experimental methods comply with international standards), risk management files, and some stability data (if conditions match). However, reference intervals, clinical performance, and transport simulation must be localized. For multi-country registration, building a core performance file package containing all internationally applicable data, then adding local data as needed, can significantly reduce rework and deficiency risks. Additionally, certificate control rights and the qualifications of the local agent are critical; any change in agent or certificate expiration may trigger re-review of performance evidence.

Frequently Asked Questions

Q1: Who should issue the performance verification report?

The report is typically issued by the manufacturer’s own laboratory or a contracted third-party laboratory. The laboratory should be ISO 15189 or ISO 17025 accredited, or at least demonstrate that its quality system complies with GLP. For clinical performance evaluation, it is generally conducted at qualified healthcare institutions.

Q2: Can literature data be used if local population reference intervals are unavailable?

Yes, but you must provide the literature source, a statement of population matching, and a rationale for its use. For markers with significant racial variation (e.g., HbA1c, vitamin D), local population verification is strongly recommended; otherwise, deficiency letters are likely.

Q3: What does a transport simulation study involve?

The study simulates actual transport conditions in the target country, including temperature, humidity, vibration, and pressure. Reference standards such as ISTA 2A and ASTM D4169 are commonly used. Environmental parameters are recorded, and product performance is tested after simulation to demonstrate that functionality was not compromised.

Applicability and Scope

Content compiled by AIMEILI Regulatory Editorial Team, professionally reviewed by the AIMEILI Medical Device International Registration Project Group. Sources are prioritized from official regulatory authorities, international organizations, standards organizations, and publicly available regulatory materials; industry media and project experience are used only as auxiliary reference. This article is intended for preliminary understanding, documentation preparation, and project planning, and does not replace formal requirements, test conclusions, or legal advice from target country regulatory authorities.